Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

172.37B

Market cap172.37B

Price-Earnings ratio

20.67

Price-Earnings ratio20.67

Dividend yield

2.28%

Dividend yield2.28%

Average volume

5.53M

Average volume5.53M

High today

$141.06

High today$141.06

Low today

$137.15

Low today$137.15

Open price

$138.75

Open price$138.75

Volume

5.44M

Volume5.44M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$93.37

52 Week low$93.37

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $141.06, giving the company a market capitalization of 172.37B. It carries a P/E multiple of 20.67 and pays a dividend yield of 2.3%.

During the trading session on 2026-04-08, Gilead Sciences(GILD) shares reached a daily high of $141.06 and a low of $137.15. At a current price of $141.06, the stock is +2.9% higher than the low and still 0.0% under the high.

Trading activity shows a volume of 5.44M, compared to an average daily volume of 5.53M.

The stock's 52-week range extends from a low of $93.37 to a high of $157.29.

GILD News

TipRanks 11h

Leerink sees Gilead’s $5B Tubulis buy as ‘more than an oncology bolt-on’

Leerink notes Gilead (GILD) announced a definitive agreement to acquire privately held Tubulis for a total potential deal value of $5B. The firm likes the strat...

Seeking Alpha 16h

Gilead to acquire Tubulis GmbH for $5B

Gilead (GILD) said on Tuesday that it would acquire Germany-based biotechnology firm Tubulis GmbH for $5B to build on its oncology pipeline. The acquisition wi...

The Wall Street Journal 16h

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

Gilead said it plans to fund the acquisition, slated to close in the second quarter, with cash on hand and senior unsecured notes. Mike Blake/REUTERS Gilead Sc...

Analyst ratings

75%

of 32 ratings

Buy

75%

Hold

21.9%

Sell

3.1%

More GILD News

Nasdaq 16h

Gilead Sciences To Acquire Germany's Tubulis For Up To $5 Bln

(RTTNews) - Gilead Sciences, Inc. (GILD) announced Tuesday it has entered into a definitive agreement to acquire German biotechnology company Tubulis GmbH to bu...

Simply Wall St 2d

Assessing Gilead Sciences Valuation After Its Strong Multi Year Share Price Run

Advertisement Gilead Sciences stock after a solid multi year run Gilead Sciences (GILD) continues to attract interest after multi year total returns, includin...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.